MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement.

On March31, 2017, we entered into a License Agreement and a
Supply Agreement with CyDex Pharmaceuticals,Inc. Under the terms
of the License Agreement, CyDex has granted us an exclusive
license to use CyDexs Captisol drug formulation system and
related intellectual property in connection with the development
and commercialization of ganaxolone in any and all therapeutic
uses in humans, with some exceptions.

As consideration for this license, we paid an upfront fee and are
required to make additional payments in the future upon
achievement of various specified clinical and regulatory
milestones. We will also be required to pay royalties to CyDex on
sales of ganaxolone, if successfully developed, in the low-to-mid
single digits based on levels of annual net sales.

Under the terms of the Supply Agreement, we are required to
purchase all of our requirements for Captisol with respect to
ganaxolone from CyDex, and CyDex is required to supply us with
Captisol for such purposes, subject to certain limitations.

A copy of the License Agreement and Supply Agreement, with
certain terms omitted, are attached as Exhibits 10.1 and 10.2 to
this report and is incorporated herein by reference. Application
has been made to the Securities and Exchange Commission for
confidential treatment of certain provisions. Omitted material
for which confidential treatment has been requested has been
filed separately with the Securities and Exchange Commission. The
descriptions of the License Agreement and Supply Agreement are a
summary only and are qualified in their entirety by reference to
Exhibits 10.1 and 10.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

About MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) Recent Trading Information

MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) closed its last trading session down -0.03 at 1.56 with 1,179,858 shares trading hands.